|
rs9967983
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two independent SNPs in SOD1 were inversely associated with prostate cancer recurrence in additive models (rs17884057 hazard ratio [HR] = 0.49, 95%CI: 0.25-0.96; rs9967983 HR = 0.62, 95% CI: 0.40-0.95).
|
24038157 |
2013 |
|
rs996427
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Evaluating genetic risk for prostate cancer among Japanese and Latinos.
|
22923026 |
2012 |
|
rs9939609
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.
|
20976066 |
2010 |
|
rs9939609
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs9939609 polymorphism in the FTO gene has recently been implicated as a risk factor for some types of cancer, such as breast, pancreatic, and prostate cancers.
|
29260910 |
2018 |
|
rs9915936
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found no statistically significant association between controls and prostate cancer for other seven SNPs of AXIN2 including Exon1-148 C/T (rs2240308), Exon1-432 T/C (rs2240308), Exon5-1365 G/A (rs9915936), Exon5-1386 C/T (rs1133683), Intron5-1712+19 T/G, Exon7-2062 C/T, and Intron7-2141+73 G/A (rs4072245) (P>0.05).
|
21069480 |
2011 |
|
rs9900242
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two signals were seen in regions already reported for prostate cancer risk. rs7014346 at 8q24.21 was marginally associated with aggressive prostate cancer in the BPC3 trial (p=1.6×10(-6)), whereas after meta-analysis by PRACTICAL the summary OR was 1.21 (95% CI 1.16-1.27; p=3.22×10(-18)). rs9900242 at 17q24.3 was also marginally associated with aggressive disease in the meta-analysis (OR 0.90, 95% CI 0.86-0.94; p=2.5×10(-6)).
|
25277271 |
2015 |
|
rs9889335
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Multiple newly identified loci associated with prostate cancer susceptibility.
|
18264097 |
2008 |
|
rs9852810
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among Caucasian men, one SNP in MLH1 (rs9852810) was associated with overall prostate cancer risk [odds ratio, 1.21; 95% confidence interval (95% CI), 1.02, 1.44; P = 0.03], more aggressive prostate cancer (odds ratio, 1.49; 95% CI, 1.15, 1.91; P < 0.01), and prostate cancer recurrence (hazard ratio, 1.83; 95% CI, 1.18, 2.86; P < 0.01), but not prostate cancer-specific mortality.
|
20056646 |
2010 |
|
rs985081
|
|
C |
0.700 |
GeneticVariation |
GWASDB |
A genome-wide association study of prostate cancer in West African men.
|
24185611 |
2014 |
|
rs980171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three adjacent SNPs centromeric to prostate cancer risk-region 2 (rs12334903, rs1456310, and rs980171) were associated with testosterone (P < 1.1 x 10(-3)) and bioavailable testosterone (P < 6.3 x 10(-4)).
|
20551303 |
2010 |
|
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
15474988 |
2005 |
|
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy.
|
18452169 |
2008 |
|
rs968098233
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished.
|
15919721 |
2005 |
|
rs9666607
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs of CD44 (rs9666607), ABCC1 (rs35605 and rs212091) and GDF15 (rs1058587) were associated with PCa survival and predicted to be functional.
|
29726910 |
2018 |
|
rs9658655
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the CHGA Glu264Asp polymorphism men with the GG genotype were at 2.05 times higher risk for prostate cancer than men with the CC genotype (p = 0.014).
|
20663522 |
2010 |
|
rs9656816
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Multiple newly identified loci associated with prostate cancer susceptibility.
|
18264097 |
2008 |
|
rs9656816
|
|
|
0.700 |
GeneticVariation |
GWASDB |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
|
rs9651118
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, our data provide rationale to further validate the clinical utility of <i>MTHFR</i> rs9651118 as a biomarker for prognosis in prostate cancer.
|
27916838 |
2016 |
|
rs964184
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association between rs964184 and prostate cancer risk was stronger among homozygous carriers of the minor allele (OR = 0.27; 95% CI: 0.09, 0.83).
|
24623848 |
2014 |
|
rs9623117
|
|
C |
0.700 |
GeneticVariation |
GWASDB |
Sequence variants at 22q13 are associated with prostate cancer risk.
|
19117981 |
2009 |
|
rs9608380
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This is the first study to analyze the association between genetic variations in the CRYBB2 gene with PCa. rs9608380, associated with PCa, is a potentially functional variant.
|
25964531 |
2015 |
|
rs9600079
|
|
T |
0.710 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population.
|
20676098 |
2010 |
|
rs9600079
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We found that three of the five genetic variants were associated with prostate cancer risk (P = 4.33 × 10(-8) for rs12653946 at 5p15, 4.43 × 10(-5) for rs339331 at 6q22 and 8.42 × 10(-4) for rs9600079 at 13q22, respectively).
|
22114074 |
2012 |
|
rs953038635
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study.
|
17465268 |
2007 |
|
rs953038635
|
|
|
0.020 |
GeneticVariation |
BEFREE |
No significant association was found between the Ala-9Val and Ala-16Val polymorphisms in MnSOD and prostate cancer susceptibility.
|
19647296 |
2009 |